Previous close | 2.7800 |
Open | 2.7500 |
Bid | 2.6700 x 100 |
Ask | 2.8100 x 100 |
Day's range | 2.6500 - 2.8130 |
52-week range | 0.7050 - 6.8500 |
Volume | |
Avg. volume | 233,117 |
Market cap | 39.532M |
Beta (5Y monthly) | 1.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6700 |
Earnings date | 12 Jul 2024 - 16 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.00 |
We can readily understand why investors are attracted to unprofitable companies. For example, Lexaria Bioscience...
Insiders were net buyers of Lexaria Bioscience Corp.'s ( NASDAQ:LEXX ) stock during the past year. That is, insiders...
NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/e7Vus With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecu